New Delhi: The Serum Institute of India (SII) has received approval of the Drugs Controller General of India (DCGI) for conducting the Phase 2 and 3 human clinical trials of the Covid-19 vaccine candidate developed by Oxford University, news agency PTI reported.
The DCGI has given approval to SII to carry out phase-II, III clinical trial based on the recommendations of the Subject Expert Committee (SEC) after a thorough evaluation.
The Pune-based SII has signed an agreement to manufacture the potential vaccine developed by University of Oxford’s Jenner Institute in collaboration with British-Swedish company AstraZeneca.
Phase 2 and 3 clinical trials of the Oxford vaccine candidate is on in the United Kingdom, Phase 3 in Brazil and Phase 1 and 2 in South Africa.